BrightGene Bio-Medical Technology Co., Ltd. (SHA:688166)

China flag China · Delayed Price · Currency is CNY
43.21
+2.83 (7.01%)
At close: Jun 18, 2026
Market Cap18.81B -8.4%
Revenue (ttm)1.30B +9.1%
Net Income50.85M -63.2%
EPS0.12 -63.7%
Shares Out 435.23M
PE Ratio369.85
Forward PEn/a
Dividend0.02 (0.04%)
Ex-Dividend DateJun 9, 2026
Volume17,008,570
Open40.53
Previous Close40.38
Day's Range39.85 - 45.43
52-Week Range38.89 - 122.59
Beta0.21
AnalystsStrong Buy
Price Target38.00 (-12.06%)
Earnings DateAug 24, 2026

About SHA:688166

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, inc... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 1,196
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688166
Full Company Profile

Financial Performance

In 2025, SHA:688166's revenue was 1.22 billion, a decrease of -4.59% compared to the previous year's 1.28 billion. Earnings were 54.51 million, a decrease of -71.18%.

Financial Statements